Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KCNA2 | P16389 | 1/20 | 0.38 |
| ▸ | KCNA4 | P22459 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25383713 | 0.85 | PTPN1 (0.50) | KCNA3CYP3A4KCNA2KCNA4KCNA5 | |
| SCHEMBL11106706 | 0.84 | CYP3A4 (0.48) | KCNA3CYP3A4MEN1HPGDKMT2A | |
| SCHEMBL684711 | 0.84 | KCNA3 (0.49) | KCNA3CYP3A4 | |
| SCHEMBL4108349 | 0.83 | KCNA3 (0.47) | KCNA3CYP3A4LMNAUSP2MAPK1 | |
| SCHEMBL5589033 | 0.83 | KDM4E (0.45) | KCNA3CYP3A4MEN1HPGDKMT2A | |
| SCHEMBL25384697 | 0.82 | PTPN1 (0.52) | KCNA3CYP3A4LMNAUSP2MAPK1 | |
| Potassium Ion SCHEMBL29141174 | 0.79 | KCNA3 (0.38) | KCNA3CYP3A4LMNASMN1; SMN2 | |
| SCHEMBL9752628 | 0.78 | CYP3A4 (0.52) | KCNA3CYP3A4MEN1HPGDKMT2A | |
| SCHEMBL25952524 | 0.78 | CYP3A4 (0.52) | KCNA3CYP3A4MEN1HPGDKMT2A | |
| SCHEMBL25952538 | 0.78 | CYP3A4 (0.52) | KCNA3CYP3A4MEN1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110287106-A1 | COGNITIVE IMPAIRMENT AMELIORANT | JAPAN ROYAL JELLEY CO., LTD. (JP) | 2011-11-24 | — | — | US | claimed |
| EP-2311472-A1 | COGNITIVE DISORDER-AMELIORATING AGENT | Japan Royal Jelly Co., Ltd. (JP) | 2011-04-20 | — | — | EP | claimed |
| US-11559512-B2 | Composition for prevention, alleviation, and/or treatment of heat illness | TOYO UNIVERSITY (JP) | 2023-01-24 | — | — | US | disclosed |
| CN-110498784-B | Nobiletin derivatives or pharmaceutically acceptable salts thereof, and preparation method and application thereof | 广东克冠达医药科技有限公司 | 2022-06-14 | — | — | CN | disclosed |
| US-20200297694-A1 | COMPOSITION FOR PREVENTION, ALLEVIATION, AND/OR TREATMENT OF HEAT ILLNESS | TOYO UNIVERSITY (JP) | 2020-09-24 | — | — | US | disclosed |
| EP-3689345-A1 | COMPOSITION FOR PREVENTION, ALLEVIATION, AND/OR TREATMENT OF HEAT STROKE | Toyo University (JP) | 2020-08-05 | — | — | EP | disclosed |
| EP-2311472-B1 | COGNITIVE DISORDER-AMELIORATING AGENT | JAPAN ROYAL JELLY CO LTD (JP) | 2014-03-05 | — | — | EP | disclosed |
| EP-2311472-B1 | COGNITIVE DISORDER-AMELIORATING AGENT | JAPAN ROYAL JELLY CO LTD (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20130129832-A1 | COGNITIVE IMPAIRMENT AMELIORANT | TOHOKU UNIVERSITY (JP) | 2013-05-23 | — | — | US | disclosed |
| US-20130129832-A1 | COGNITIVE IMPAIRMENT AMELIORANT | TOHOKU UNIVERSITY (JP) | 2013-05-23 | — | — | US | disclosed |
| US-20110287106-A1 | COGNITIVE IMPAIRMENT AMELIORANT | JAPAN ROYAL JELLEY CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
| US-20110287106-A1 | COGNITIVE IMPAIRMENT AMELIORANT | JAPAN ROYAL JELLEY CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
| EP-2311472-A1 | COGNITIVE DISORDER-AMELIORATING AGENT | Japan Royal Jelly Co., Ltd. (JP) | 2011-04-20 | — | — | EP | disclosed |
| EP-2311472-A1 | COGNITIVE DISORDER-AMELIORATING AGENT | Japan Royal Jelly Co., Ltd. (JP) | 2011-04-20 | — | — | EP | disclosed |
| US-4532254-A | Inhibitor of aldose reductase | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1985-07-30 | — | — | US | disclosed |
| EP-0118571-A1 | Inhibitor of aldose reductase | Kaken Pharmaceutical Co., Ltd. (JP) | 1984-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559512-B2 | Composition for prevention, alleviation, and/or treatment of heat illness | TNF, HSF1, HSP90AA1 | KCNA3 2497/4885CYP3A4 1707/4885MEN1 3508/4885 |
| US-20130129832-A1 | COGNITIVE IMPAIRMENT AMELIORANT | CHAT, ACHE, PSEN1 | KCNA3 4482/4885CYP3A4 4098/4885MEN1 3488/4885 |
| US-20200297694-A1 | COMPOSITION FOR PREVENTION, ALLEVIATION, AND/OR TREATMENT OF HEAT ILLNESS | TNF, HSF1, HSP90AA1 | KCNA3 2497/4885CYP3A4 1707/4885MEN1 3508/4885 |
| US-20110287106-A1 | COGNITIVE IMPAIRMENT AMELIORANT | CHAT, ACHE, PSEN1 | KCNA3 4482/4885CYP3A4 4098/4885MEN1 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.